Bank Julius Baer & Co. Ltd Zurich lowered its position in Catalent, Inc. (NYSE:CTLT – Get Rating) by 16.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,562 shares of the company's stock after selling 3,960 shares during the period. Bank Julius Baer & Co. Ltd Zurich's holdings in Catalent were worth $1,488,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Tokio Marine Asset Management Co. Ltd. boosted its position in Catalent by 22.5% in the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,043 shares of the company's stock valued at $326,000 after buying an additional 558 shares during the last quarter. US Bancorp DE boosted its position in Catalent by 1.4% in the 3rd quarter. US Bancorp DE now owns 19,237 shares of the company's stock worth $1,392,000 after purchasing an additional 272 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its position in Catalent by 12.0% in the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 90,954 shares of the company's stock worth $9,759,000 after purchasing an additional 9,723 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in Catalent by 88.1% in the 2nd quarter. Illinois Municipal Retirement Fund now owns 6,028 shares of the company's stock worth $647,000 after purchasing an additional 2,824 shares in the last quarter. Finally, Private Advisor Group LLC boosted its position in Catalent by 98.5% in the 2nd quarter. Private Advisor Group LLC now owns 5,870 shares of the company's stock worth $630,000 after purchasing an additional 2,913 shares in the last quarter. Hedge funds and other institutional investors own 99.38% of the company's stock.

Catalent Stock Performance

Shares of Catalent stock opened at $49.57 on Wednesday. The business has a 50-day moving average of $46.22 and a 200 day moving average of $72.04. Catalent, Inc. has a 12 month low of $40.69 and a 12 month high of $115.33. The stock has a market capitalization of $8.92 billion, a price-to-earnings ratio of 21.18, a price-to-earnings-growth ratio of 3.63 and a beta of 1.24. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.86 and a quick ratio of 2.08.

Insider Buying and Selling at Catalent

In other Catalent news, SVP Michael J. Grippo sold 2,451 shares of the stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $65.83, for a total value of $161,349.33. Following the sale, the senior vice president now owns 17,792 shares of the company's stock, valued at approximately $1,171,247.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Michael J. Grippo sold 2,451 shares of the firm's stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the sale, the senior vice president now owns 17,792 shares of the company's stock, valued at approximately $1,171,247.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Manja Boerman sold 780 shares of the firm's stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $51.70, for a total value of $40,326.00. Following the sale, the insider now directly owns 15,860 shares in the company, valued at approximately $819,962. The disclosure for this sale can be found here. 0.58% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on CTLT shares. Barclays lowered their price objective on Catalent from $62.00 to $58.00 and set an "overweight" rating on the stock in a research report on Tuesday. KeyCorp reduced their target price on Catalent from $125.00 to $85.00 and set an "overweight" rating for the company in a research note on Wednesday, November 2nd. TheStreet downgraded Catalent from a "b-" rating to a "c+" rating in a research note on Friday, October 28th. Argus downgraded Catalent from a "buy" rating to a "hold" rating in a research note on Monday, November 7th. Finally, Robert W. Baird reduced their price objective on Catalent from $123.00 to $75.00 in a research note on Wednesday, November 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $92.40.

About Catalent

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Articles

• Get a free copy of the StockNews.com research report on Catalent (CTLT)
• Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
• How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
• Is the Pain Over for Baudax Bio Investors after a 70% Spike?
• Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
• When Will Crane Holdings Take Flight?

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.